> Detailanzeige

Faller, Eamonn; Wyse, Adrianne; Barry, Rachel; Conlon, Kevin; Everard, Cormac; Finnegan, Paula; Foran, Claire; Herlihy, Emer; Kerr, Gerry; Lapthorne, Susan; McGreal-Bellone, Aimee; Morrissey, Edmond; O’Sullivan, Deirdre; O’Sullivan, Grainne; Eustace, Joseph A; Spillane, Declan; Dempsey, Catherine; Benson, John; Prentice, Mike; Gallagher, John; MacSharry, John; Fanning, Liam J; O’Riordan, Stephen; Horgan, Mary;

Seroprevalence study of SARS-CoV-2 antibodies in healthcare workers following the first wave of the COVID-19 pandemic in a tertiary-level hospital in the south of Ireland

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Seroprevalence study of SARS-CoV-2 antibodies in healthcare workers following the first wave of the COVID-19 pandemic in a tertiary-level hospital in the south of Ireland
  • Beteiligte: Faller, Eamonn; Wyse, Adrianne; Barry, Rachel; Conlon, Kevin; Everard, Cormac; Finnegan, Paula; Foran, Claire; Herlihy, Emer; Kerr, Gerry; Lapthorne, Susan; McGreal-Bellone, Aimee; Morrissey, Edmond; O’Sullivan, Deirdre; O’Sullivan, Grainne; Eustace, Joseph A; Spillane, Declan; Dempsey, Catherine; Benson, John; Prentice, Mike; Gallagher, John; MacSharry, John; Fanning, Liam J; O’Riordan, Stephen; Horgan, Mary;
  • Erschienen: BMJ, 2021
  • Erschienen in: BMJ Open, 11 (2021) 6, Seite e051415
  • Sprache: Englisch
  • DOI: 10.1136/bmjopen-2021-051415
  • ISSN: 2044-6055
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: ObjectiveThis study investigated seroprevalence of SARS-CoV-2-specific IgG antibodies, using the Abbott antinucleocapsid IgG chemiluminescent microparticle immunoassay (CMIA) assay, in five prespecified healthcare worker (HCW) subgroups following the first wave of the COVID-19 pandemic.SettingAn 800-bed tertiary-level teaching hospital in the south of Ireland.ParticipantsSerum was collected for anti-SARS-CoV-2 nucleocapsid IgG using the Abbott ARCHITECT SARS-CoV-2 IgG CMIA qualitative assay, as per the manufacturer’s specifications.The groups were as follows: (1) HCWs who had real-time PCR (RT-PCR) confirmed COVID-19 infection (>1-month postpositive RT-PCR); (2) HCWs identified as close contacts of persons with COVID-19 infection and who subsequently developed symptoms (virus not detected by RT-PCR on oropharyngeal/nasopharyngeal swab); (3) HCWs identified as close contacts of COVID-19 cases and who remained asymptomatic (not screened by RT-PCR); (4) HCWs not included in the aforementioned groups working in areas determined as high-risk clinical areas; and (5) HCWs not included in the aforementioned groups working in areas determined as low-risk clinical areas.ResultsSix of 404 (1.49%) HCWs not previously diagnosed with SARS-CoV-2 infection (groups 2–5) were seropositive for SARS-CoV-2 at the time of recruitment into the study.Out of the 99 participants in group 1, 72 had detectable IgG to SARS-CoV-2 on laboratory testing (73%). Antibody positivity correlated with shorter length of time between RT-PCR positivity and antibody testing.Quantification cycle value on RT-PCR was not found to be correlated with antibody positivity.ConclusionsSeroprevalence of SARS-CoV-2 antibodies in HCWs who had not previously tested RT-PCR positive for COVID-19 was low compared with similar studies.
  • Zugangsstatus: Freier Zugang